Randomized trial to assess the safety, tolerability and efficacy of arterolane-piperaquine, arterolane-piperaquine+mefloquine and artemether-lumefantrine

Randomized trial to assess the safety, tolerability and efficacy of arterolane-piperaquine, arterolane-piperaquine+mefloquine and artemether-lumefantrine. Number of subjects 219. We obtain parasite clearance half lives and travel surveys.

Info

Study ID

1262

Key People

  • Philip Bejon

    • KEMRI Wellcome Trust Research Programme, Kenya

  • Arjen Dondorp

    • Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand
    • Centre for Tropical Medicine and Global Health, University of Oxford, UK

  • Mainga Hamaluba

    • KEMRI Wellcome Trust Research Programme, Kenya

  • Mallika Imwong

    • Mahidol University, Thailand

  • Rob van der Pluijm

    • Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand

Summary

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Locations

Kilifi

Summary

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers